从烟台市市场监管局获悉，为抢抓产业高质量发展战略机遇，加快构建现代化医疗器械产业体系，烟台 市立足"1+3+X"生物医药产业总体布局，制定出台《烟台市医疗器械产业发展规划(2025—2029年)》(以 下简称《规划》)，明确未来五年产业发展的目标路径、空间布局、攻坚任务与保障措施，全力打造具 有国际竞争力的医疗器械创新高地与产业集群。 在产业生态培育上，新引进2—3家具备核心研发能力的医疗器械企业在烟设立总部或研发生产基地，同 步培育一批专精特新、单项冠军、瞪羚企业；依托烟台各区市特色优势，高标准建成1个核心产业园 区，打造3—5个特色产业基地，形成覆盖产品研发、生产、流通、医疗服务的产业垂直生态体系。 齐鲁晚报.齐鲁壹点秦雪丽通讯员孙洪安 剑指百亿规模 构建高能级产业生态 《规划》锚定"集群联动、创新驱动、生态融合、国际竞合"核心目标，提出到2029年，全市医疗器械产 业总体规模力争突破100亿元，其中高附加值医疗器械占比达到40%以上，实现产业规模与发展质量双 提升。 四区联动聚合力。芝罘区、莱山区、牟平区、黄渤海新区四区联动，重点布局涉氧器械、康复辅具、医 学影像设备、血液诊断、类器官芯片、生物再生材料 ...

Core Viewpoint - Ruixin Medical is committed to developing an all-automatic AI vascular interventional surgical robot to enhance early diagnosis and precise treatment of cardiovascular diseases, aiming to create a closed-loop diagnostic and treatment system [1][3]. Company Developments - The all-automatic AI vascular interventional surgical robot is expected to complete animal surgeries using AI automation in the second half of this year, following prototype production and simulation experiments [3]. - The robot aims to assist in simple and repetitive surgical procedures under the supervision of doctors, while providing enhanced support for more challenging surgeries [3][4]. Industry Challenges - The cardiovascular treatment field faces three main challenges: heavy physical burden on doctors due to lead aprons, variability in manual operations leading to training difficulties for younger doctors, and uneven distribution of medical resources across the country [3][4]. Technological Integration - Ruixin Medical's robot integrates a tri-party collaboration among doctors, intelligent systems, and execution terminals, allowing for natural language interaction and automated surgical operations [4]. - The short-term goals include reducing radiation exposure, alleviating the burden of lead aprons, lowering repetitive tasks, shortening training periods, standardizing surgical quality, and supporting remote medical services [4]. Regulatory Environment - The launch of the robot coincides with the National Medical Products Administration's new measures to support high-end medical device innovation, marking a significant step towards the "fully automatic" intelligent era in vascular intervention [5]. Expert Insights - Experts agree that the integration of AI and fully automatic vascular interventional robots represents a major trend for the future, emphasizing the importance of overcoming challenges to lead in this innovative field [5].

Group 1 - The announcement from the National Medical Products Administration supports significant innovation in high-end medical devices, focusing on core technologies such as brain-computer interfaces, artificial intelligence, and medical robots [1][2] - The announcement outlines key areas for development, including medical robots, high-end medical imaging equipment, AI medical devices, and new biological materials, and proposes measures to optimize approval processes and enhance regulatory frameworks [2][3] - The high-end medical device market in China is expanding, with an average annual growth rate exceeding 20%, particularly in areas like medical robots and AI medical devices, which are experiencing explosive growth [3][4] Group 2 - Companies are actively advancing technology applications in high-end medical devices, with many listed firms strategically positioning themselves in AI and medical robotics to seize development opportunities [4] - Several companies have developed innovative products, such as the ZAP-X radiation surgery robot and a fully magnetic levitation artificial heart, indicating a trend towards high-quality development in the sector [4] - Collaboration between companies, medical institutions, and research organizations is emphasized to accelerate the transformation of research results into market-ready products [4]